Reduction of Ga-PSMA renal uptake with mannitol infusion: preliminary results.

PURPOSE

Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with Ga or Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and mannitol acts as an osmotic diuretic in these tubules. We investigated the potential of mannitol to reduce renal uptake of Ga-PSMA.

METHODS

Kidney uptake (SUVmax) was calculated in nine patients undergoing Ga-PSMA PET/CT at baseline (b-PET/CT) and after intravenous infusion of 500 ml of 10% mannitol (m-PET/CT). Two different infusion schemes for mannitol were used: (1) 500 ml mannitol was infused over 40 min after Ga-PSMA administration (A-infusion) and (2) 250 ml mannitol was infused over 15 min before and again after Ga-PSMA administration (B-infusion).

RESULTS

In patients receiving the A-infusion, mean SUV increased by 11.9% and 7.4% in the right and left kidney, respectively. In patients receiving the B-infusion, mean SUV decreased by 24.3% and 22.4% in the right and left kidney, respectively.

CONCLUSION

Our preliminary findings indicate that mannitol may play a role in reducing off-target Ga-PSMA renal uptake. Administration of the osmotic diuretic should be rapid and start before Ga-PSMA injection. These results warrant dosimetric studies in patients treated with Lu-PSMA to find the best scheme for mannitol administration.